NCT00876876撤回3 期
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 300
- 主要终点
- To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.
研究概览
简要总结
To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and Women with age greater than or equal to 18 years.
- •Prior successful participation in a randomized, blinded, placebo-controlled Phase 3 lixivaptan study of hyponatremia in Heart Failure (Protocol CK-LX3401) with evidence of continued need for therapy as follows:
- •Patient completed full course of treatment (e.g., either placebo or lixivaptan). Treatment assignments for Protocol CK-LX3401 will not be unblinded prior to participation in the extension study.
- •Baseline serum sodium concentration < 135 mEq/L following a 30 day post treatment follow-up period in a lixivaptan hyponatremia parent trial. Repeat measures of serum sodium are allowed; the last serum sodium result within 24 hours prior to randomization will serve as the qualifying measurement.
- •The patient has clinical evidence of volume overload with at least one of the following:
- •Pulmonary congestion (rales)
- •Peripheral edema
- •Increased jugular venous pressure and/or hepatic congestion with ascites
- •Chest x-ray consistent with CHF; OR
- •Plasma BNP ≥150 pg/mL or NT pro-BNP ≥ 450 pg/mL
排除标准
- •Women who are pregnant (positive pregnancy test), breastfeeding or who will not adhere to the reproductive precautions as outlined in this protocol and in the informed consent form.
- •Inability to provide informed consent.
- •Acute severe hyponatremia with overt symptoms of hyponatremia requiring immediate medical intervention (e.g., coma, seizures).
- •Acute or transient hyponatremia (e.g., associated with head trauma or postoperative state).
- •Hyponatremia in hypovolemic states. Hypovolemia is defined as the presence of clinical evidence of fluid volume depletion.
- •Euvolemic Hyponatremia (e.g., SIADH, etc.). Euvolemic hyponatremia is defined as low serum sodium in the presence of normal total body sodium due to mild to moderate increases in total body water without edema.
研究组 & 干预措施
Placebo QD or BID
Placebo Comparator
Placebo QD or BID
干预措施: Lixivaptan (Drug)
Lixivaptan QD or BID
Experimental
Lixivaptan QD or BID
干预措施: Lixivaptan (Drug)
结局指标
主要结局
To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.
时间窗: 12 weeks
次要结局
- To demonstrate that after 12 weeks of open-label lixivaptan treatment, improvements in the time to complete the Trail Making Test (Part B) will be maintained in patients continuing to receive lixivaptan.(20 weeks)
研究者
相似试验
已完成
3 期
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient EvaluationHyponatremiaNCT00578695CardioKine Inc.652
已完成
不适用
0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill ChildrenHyponatremiaNCT01301274Hospital General de Niños Pedro de Elizalde66
终止
4 期
Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With AscitesHyponatremia and Extracellular Fluid in CirrhoticNCT01552590Korea Otsuka Pharmaceutical Co., Ltd.74
已完成
不适用
Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation PatientsHeart Assist DeviceHyponatremicHeart FailureNCT05408104University of Chicago28
已完成
4 期
Tolvaptan in Hyponatremic Cancer PatientsAdvanced CancersNCT01199198M.D. Anderson Cancer Center52